Rodríguez, Isabel
López-Caro, Juan Carlos
Gonzalez-Carranza, Silvia
Cerrato, Maria Elena
De Prado, Maria Mar
Gomez-Molleda, Francisca
Pinel, Margarita
Saiz, Maria Teresa
Fuentes, Carmen
Barreiro, Esther
Santibáñez, Miguel
Article History
Received: 28 March 2023
Accepted: 7 August 2023
First Online: 11 August 2023
Competing interests
: JCLC has received speaker’s and/or consulting fees from Astra Zeneca, Almirall, Bial, Boehringer-Ingelheim, Chiesi, Esteve, Ferrer, GSK, Lilly, Menarini, Mundipharma, MSD, Novartis, Novo, Rovi, Teva, Viatris and Zambón. MP has received speaker’s and/or consulting fees from Astra Zeneca, GSK, Teva, Mylan, Bial, Novartis, Boehringer-Ingelheim and Pfizer. MS has received speaker’s and/or consulting fees from GSK, Teva, and Boehringer-Ingelheim. MEC has received consulting fees from Teva. These authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The rest of authors declare that they have no conflict of interest.